Welcome to our 67th newsletter!
Remember! In 2009, Martine Barkats, then at Genethon, demonstrated in mice the efficacy of the vector and its systemic administration in the central nervous system to treat spinal muscular atrophy. Thanks in particular to this work (license agreement Genethon-AveXis announced last March 14th), AveXis is now developing a gene therapy whose results are spectacular for the children included in the trial in the United States. The test should be extended to Europe – and in particular to France with I-Motion- by the end of the year.
Save the date! Myology 2019, the 6th International Congress of Myology organized by AFM-Telethon, will take place between March 25-28 2019 at the Bordeaux-Lac Convention Centre, in France. The world’s leading experts in myology will be present to exchange on all myology-related topics, with an ever-increasing focus on therapeutic innovations for neuromuscular diseases.
> Access the 67th newsletter of the Institute of Myology
